Related Experiment Video

Updated: May 25, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

Libero Santarpia1, Scott M Lippman, Adel K El-Naggar

  • 1The University of Texas M.D. Anderson Cancer Center, Department of Pathology, Houston, TX,USA.

Expert Opinion on Therapeutic Targets
|January 14, 2012
PubMed
Abstract

Insights

Targeting the RAS-MAPK pathway with MEK and RAF kinase inhibitors shows promise in cancer treatment, with genetic analysis guiding therapy and future research focusing on overcoming resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The MAPK pathway is crucial in cell signaling, regulating growth, differentiation, and apoptosis.
  • Aberrant RAS-MAPK pathway activation, due to mutations in RAS or RAF genes, drives tumorigenesis.
  • This pathway is a significant target for developing novel cancer therapeutics.

Purpose of the Study:

  • To review the biological role and disregulation of the RAS-MAPK pathway in cancer.
  • To discuss the development and clinical application of small-molecule inhibitors targeting this pathway.
  • To evaluate the efficacy and challenges of RAS-MAPK pathway inhibitors in cancer therapy.

Main Methods:

  • Review of literature on the RAS-MAPK signaling cascade and its role in cancer.
  • Analysis of preclinical and clinical data for small-molecule inhibitors targeting MEK and RAF kinases.
  • Examination of genetic mutation analysis as a predictive biomarker for treatment response.

Main Results:

  • MEK and RAF kinase inhibitors demonstrate significant efficacy in clinical trials.
  • These inhibitors exhibit manageable side effect profiles.
  • Genetic analysis of RAS and BRAF mutations is essential for predicting treatment response and avoiding adverse effects.

Conclusions:

  • RAF and MEK inhibitors are effective anticancer agents with acceptable toxicity.
  • RAS/BRAF mutation status is a critical biomarker for patient selection and treatment optimization.
  • Further research into RAS-MAPK regulation and resistance mechanisms is needed to develop superior combination therapies.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...